About Vaxira

About company

Vaxira® is an immunotherapeutic agent whose formula consists of the anti-idiotype monoclonal antibody Racotumomab and aluminum hydroxide (HA), a widely used adjuvant. HA improves the production of antibodies, but it is neither immunogenic nor a hapten. It behaves like "depot" at the injection site, from which the antigen is released slowly, and induces the formation of granulomas that attract immunocompetent cells, such as plasma cells that produce antibodies. HA can directly stimulate monocytes to produce proinflammatory cytokines that can activate T cells and possibly stimulate B cell responses.